PubMed Health⌕ Search

Biomedical subjects

E Anhalt

Publications and source records attributed to E Anhalt.

5 recordsLinked to original sources

Mechanism-based inactivation of VanX, a D-alanyl-D-alanine dipeptidase necessary for vancomycin resistance.

VanX is a zinc-dependent D-Ala-D-Ala amino dipeptidase required for high-level resistance to vancomycin. The enzyme is also able to process dipeptides with bulky C-terminal amino acids [Wu, Z., Wright, G. D., and Walsh, C. T. (1995) Biochemistry 34, 2455-2463]. We took advantage of this observation to design and synthesize the dipeptide-like D-Ala-D-Gly(SPhip-CHF(2))-OH (7) as a potential mechanism-based inhibitor. VanX-mediated peptide cleavage generates a highly reactive 4-thioquinone fluoromethide which is able to covalently react with enzyme nucleophilic residues, resulting in irreversible inhibition. Inhibition of VanX by 7 was time-dependent (K(irr) = 30+/-1 microM; k(inact) = 7.3+/- 0.3 min(-1)) and active site-directed, as deduced from substrate protection experiments. Nucleophilic compounds such as sodium azide, potassium cyanide, and glutathione did not protect the enzyme from inhibition, indicating that the generated nucleophile inactivates VanX before leaving the active site. The failure to reactivate the dead enzyme by gel filtration or pH modification confirmed the covalent nature of the reaction that leads to inactivation. Inactivation was associated with the elimination of fluoride ion as deduced from (19)F NMR spectroscopy analysis and with the production of fluorinated thiophenol dimer 12. These data are consistent with suicide inactivation of VanX by dipeptide 7. The small size of the VanX active site and the presence of a number of nucleophilic side chains at the opening of the active site gorge [Bussiere, D. E., et al. (1998) Mol. Cell 2, 75-84] associated with the high observed partition ratio of 7500+/-500 suggest that the inhibitor is likely to react at the entrance of the active site cavity.

Bacterial Proteins↗

The development of good clinical practice in the EEC and in Germany.

In 1965 the first EEC Directive on the approximation of the national provisions related to medicinal products (65/65/EEC) stipulated, beside others, that the application for registration shall contain results of clinical trials. Ten years later Directive 75/318/EEC ensured uniform standards and protocols for the performance of test and trials, especially clinical trials. In May 1987 the CPMP Recommended Basis for the conduct of clinical trials addressed the general norms and scientific principles for the conduct, performance and control of clinical trials of medicinal products. Based on 75/318/EEC and on CPMP Recommended Basis, intensive discussions continued in order to further improve the measures to thoroughly protect the rights and integrity of the trial subjects, to establish the credibility of data, and to improve the ethical, scientific and technical quality of trials. As a result of these negotiations CPMP adopted in 1990 the note for guidance: GCP for Trials on Medicinal Products in the EC. In July 1991 Directive 91/507/EEC modifying 75/318/EEC was issued. It adopts the requirements to prove quality, safety and efficacy to the latest state of the art. The German Drug Law (AMG) from 1976 transposed 65/65/EEC in its substantial parts. AMG contains its own section called "Protection of the human being during the clinical trial", which only stipulates a list of general conditions to be fulfilled before starting the trial. In Dec. 1987 German Health Ministry (BMG) published a paper on the orderly execution of clinical trials to establish rules on the planning, execution, evaluation and documentation of clinical trials (BMG Principles).(ABSTRACT TRUNCATED AT 250 WORDS)

Clinical Protocols↗

Candida glabrata meningitis.

We have reported an unusual case of Candida glabrata meningitis causing acute changes in mental status in a chronically ill, elderly patient with non-insulin-dependent diabetes mellitus. Candida glabrata was identified by Gram stain, culture, and fermentation pattern from the CSF. Although the patient died of foreign body aspiration, an excellent clinical response was initially obtained with amphotericin B and 5-flucytosine. This is the first report of a symptomatic Candida glabrata meningitis.

Aged↗

Mechanism of sulphate transfer from 4-nitrophenylsulphate to phenolic acceptors via liver cytosolic sulphotransferase.

Phenol sulphotransferase from cat and rabbit liver cytosol has been investigated using 4-nitrophenylsulphate as primary sulphate donor. The first stage of the reaction involves sulphation of cofactor adenosine 3',5'-diphosphate to adenosine 3'-phosphate 5'-phosphosulphate, which in turn acts as sulphate donor for other phenolic acceptors. Adenosine 3',5'-diphosphate is regenerated in this second stage, so that the overall reaction is a sulphate transfer from 4-nitrophenylsulphate to the phenolic acceptor. High acceptor concentrations lead to inhibition of the reaction; very low concentrations give deviation from Michaelis-Menten kinetics. From the kinetic data, a mechanism is suggested in which an enzyme-adenosine 3'-phosphate 5'-phosphosulphate complex is formed in situ, with which the acceptor then interacts to give the final sulphate transfer. The system employed here is useful for the study of phenol sulphotransferase in view of the difficulty in obtaining adequate amounts of adenosine 3'-phosphate 5'-phosphosulphate from commercial sources.

Animals↗